EGFR and cancer: This negative selection in large/advanced cancers could explain the prevalence of pre‐existing KRAS mutant tumor cell subpopulations in the colorectal cancers that develop resistance to anti‐EGFR monoclonal antibody therapy [Diaz et al., 2012; Misale et al., 2012].